The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection

Diabetes, Obesity and Metabolism

Volumn 10, Issue 12, 2008, Pages 1157-1166

  Abuissa, Hussam ^a   O'Keefe Jr , James ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

ACE inhibitor; Angiotensin II; Angiotensin receptor blocker; Diabetes mellitus; Insulin; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; GLUCOSE TRANSPORT; GYNECOMASTIA; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MASTALGIA; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 55549124195     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00898.x     Document Type: Review

References (86)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, Rev edn. Atlanta, GA: U.S. Department of Health and Human Services, 2005.
2. International Diabetes Federation. Diabetes Atlas, 2nd edn. Brussels: International Diabetes Federation, 2003.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
4. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
5. O'Keefe JH, Wetzel M, Moe RR, Bronsnahan K, Lavie CJ. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2001; 37: 1-8.
6. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990; 15: 861-866.
7. Nakanishi N, Takatorige T, Fukuda H et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004; 64: 59-70.
8. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
9. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
11. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88: 2399-2403.
12. Schutta MH. Diabetes and hypertension: Epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007; 2: 124-130.
13. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
14. Watanabe K, Sekiya M, Tsuruoka T et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 1999; 17: 1161-1168.
15. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
16. DiBona GF. Neural control of renal function: Cardiovascular implications. Hypertension 1989; 13 (Pt 1): 539-548.
17. O'Keefe JH, Lurk JT, Kahatapitiya RC, Haskin JA. The renin-angiotensin-aldosterone system as a target in coronary disease. Curr Atheroscler Rep 2003; 5: 124-130.
18. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
19. Hansson L. Results of the STOP-Hypertension-2 trial. Blood Press (Suppl.) 2000; 2: 17-20.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
22. Reid CM, Johnston CI, Ryan P, Willson K, Wing LM. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: Findings from the 2nd Australian National Blood Pressure Study (abstract). Am J Hypertens 2003; 16: 11A.
23. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.
24. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.
25. Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
26. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
27. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
28. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
29. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
30. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
31. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-473.
32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
33. Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
34. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36: 281-306.
35. Khan NU, Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 2004; 5: 71-81.
36. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87: 3C-9C.
37. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2216.
38. Struthers AD Aldosterone-induced vasculopathy: A new reversible cause of cardiac death. J Renin Angiotensin Aldosterone Syst 2001; 2: 211-214.
39. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
40. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487-496.
41. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-1012.
42. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369: 201-207.
43. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2007; 16: 979-987.
44. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17 (Pt 2): 16S-20S; quiz A2-4.
45. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: H1597-H1602.
46. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91: 30H-37H.
47. Townsend RR. Angiotensin and insulin resistance: Conspiracy theory. Curr Hypertens Rep 2003; 5: 110-116.
48. Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: One more reason to block the renin-angiotensin system. J Hypertens (Suppl.) 2006; 24: S57-S63.
49. Mathur G, Noronha B, Rodrigues E, Davis G. The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. Diabetes Obes Metab 2007; 9: 617-629.
50. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 81: 796-806.
51. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006; 22: 98-107.
52. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
53. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.
54. Uehara M, Kishikawa H, Isami S et al. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans. Diabetologia 1994; 37: 300-307.
55. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997; 82: 359-363.
56. Leighton B, Budohoski L, Lozeman FJ, Challiss RA, Newsholme EA. The effect of prostaglandins E1, E2 and F2 alpha and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat. Biochem J 1985; 227: 337-340.
57. Morel Y, Gadient A, Keller U, Vadas L, Golay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26: 306-311.
58. Top C, Cingozbay BY, Terekeci H, Kucukardali Y, Onde ME, Danaci M. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30: 15-20.
59. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
60. Leung PS, de Gasparo M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 2006; 1: 197-203.
61. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133.
62. Santoro D, Natali A, Palombo C et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992; 20: 181-191.
63. Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 2003; 30: 317-329.
64. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36: 295-304.
65. Murphy GJ, Holder JC. PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000; 21: 469-474.
66. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
67. Ferder L, Inserra F, Martinez-Maldonado M. Inflammation and the metabolic syndrome: Role of angiotensin II and oxidative stress. Curr Hypertens Rep 2006; 8: 191-198.
68. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724.
69. U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
70. Parving HH, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 2001; 10: 515-522.
71. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J Am Soc Nephrol 2006; 17 (Suppl. 2): S90-S97.
72. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
73. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
74. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-545.
75. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
76. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
77. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
78. O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: Results from EPHESUS. Diabetes Obes Metab. 2007 May 8; (Epub ahead of print).
79. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-535.
80. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
81. Seed A, Gardner R, McMurray J et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9: 1120-1127.
82. Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med 2007; 8 (Suppl. 2): S22-S30.
83. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT. Insulin sensitivity in patients with essential hypertension: No influence of the ACE inhibitor enalapril. Horm Metab Res 1999; 31: 418-423.
84. Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J Hypertens 2006; 24: 1405-1412.
85. Deedwania PC, Schmieder R. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome. J Renin Angiotensin Aldosterone Syst 2006; 7 (Suppl. 1): S12-S18.
86. Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.